12月6日 Alison Gartland:Purinergic signalling pathways in bone loss and osteoarthritis


报告题目:Purinergic signalling pathways in bone loss and osteoarthritis

报告人:Alison Gartland 谢菲尔德大学

主持人:罗剑 教授

报告时间:2019年12月6日 上午10:00(周五上午)

报告地点:生命科学学院534小会议室


报告人简介:

Professor Alison Gartland studied for her PhD at The University of Liverpool, completed Post-Doctoral Researcher positions at IGMM, CNRS France and University of Massachusetts Medical School, USA. She is a Professor of Bone and Cancer Cell Biology at The University of Sheffield with expertise in purinergic signalling, bone and cancer cell biology, in vitro and in-vivo murine models of MSK disorders, including in the setting of both primary and secondary cancer. Her principal research area focus is on developing fundamental understanding of the basic cellular, molecular and genetic mechanisms responsible for musculoskeletal disease and cancer. Prof Gartland has over 50 publications in leading journals in the field of bone and cancer and has authored several book chapters on human bone cell culture techniques and osteosarcoma. She is the President of the UK Purine Club, past Secretary of the Bone Research Society, past Topic Chair of the Orthopaedic Research Society Annual Meeting Committee, and member of the International Scientific Programme Committee member for the International Purines meetings since 2014. Prof Gartland also serves on the Editorial board of Frontiers in Endocrinology (Bone Research), Purinergic Signalling and Journal of Medicines Development Sciences. She was previously a Current Opinion in Pharmacology Section Editor and editor for Scientific Reports. She currently sits on the Med4 Cancer panel for the Research Foundation - Flanders (FWO), The Children's Hospital Charity Scientific Advisory Committee and previously on the Arthritis Research UK Scientific Advisory committee. She is a regular external and internal examiner for individual higher and undergraduate degrees, as well as an external examiner for master level courses. She has been invited speaker and chairperson at numerous prestigious international conferences. Her scientific research and outreach activities regularly attract Media coverage including international press coverage, BBC World TV, BBC radio stations and various international online health and science websites.


报告内容:

It is well established that ATP is an intracellular energy source: however, it was not until relatively recently that ATP was acknowledged as the most primordial extracellular signalling molecule. Purinergic signalling is a signalling system that involves extracellular ATP and its metabolites acting outside the cell via specific cell surface P2 receptors and is now acknowledged as a ubiquitous signalling pathway modifying multiple cell types and organ systems.


Purinergic signalling in bone was first proposed in the early 1990s with the observation that extracellular ATP could raise intracellular calcium and induce secondary messenger activation – events crucial to the normal functioning of osteoblasts. Since then the expression of nearly all the P2Y and P2X receptors by osteoblasts and osteoclasts (of one species/type or another) has been reported, mediating multiple processes including triggering intracellular calcium and the respective signalling cascades that direct the fate of bone cells and ultimately help control bone homeostasis. Regulation of purinergic signalling in bone involves the co-ordinated actions of controlled release of ATP from bone cells, the expression and activity of enzymes on the surface of bone cells that can breakdown or interconvert ATP and other nucleotides and purinoceptor expression by bone cells which is tightly controlled in a temporal and spatial manner.